ESR1 and breast carcinoma: The LDFI peptide acted as a full leptin antagonist by inhibiting the leptin-induced growth and migration in both ERα-positive (MCF-7) and ERα-negative (SKBR3) breast cancer cells without interfering with cell proliferation in the absence of leptin.